{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:01Z","timestamp":1792012321029,"version":"4.4.0"},"reference-count":110,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"crossref","award":["2019 number 23604"],"award-info":[{"award-number":["2019 number 23604"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"crossref","award":["2016 number 740230"],"award-info":[{"award-number":["2016 number 740230"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. NPM1-mutated AML is recognizable by molecular techniques and immunohistochemistry, which, when combined, can solve difficult diagnostic problems (including identification of myeloid sarcoma and NPM1 mutations outside exon 12). According to updated 2022 European LeukemiaNet (ELN) guidelines, determining the mutational status of NPM1 (and FLT3) is a mandatory step for the genetic-based risk stratification of AML. Monitoring of measurable residual disease (MRD) by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage. Here, we review the criteria for appropriate diagnosis and molecular monitoring of NPM1-mutated AML.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance:<\/jats:title>\n                  <jats:p>NPM1-mutated AML represents a distinct entity in the 2022 International Consensus Classification and 5th edition of World Health Organization classifications of myeloid neoplasms. The correct diagnosis of NPM1-mutated AML and its distinction from other AML entities is extremely important because it has clinical implications for the management of AML patients, such as genetic-based risk stratification according to 2022 ELN. Monitoring of MRD by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage, e.g., whether or not to perform allogeneic hematopoietic stem cell transplantation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0144","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T19:19:16Z","timestamp":1698952756000},"page":"8-20","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Criteria for Diagnosis and Molecular Monitoring of <i>NPM1<\/i>-Mutated AML"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-5965","authenticated-orcid":false,"given":"Brunangelo","family":"Falini","sequence":"first","affiliation":[{"name":"1Institute of Hematology and Center for Hemato-Oncological Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"2Department of Medical and Molecular Genetics, King's College, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"2024010808153718500_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"2024010808153718500_bib2","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"2024010808153718500_bib3","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications","volume":"23","author":"Falini","year":"2009","journal-title":"Leukemia"},{"key":"2024010808153718500_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2024010808153718500_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2024010808153718500_bib6","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.2021012732","article-title":"Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML","volume":"138","author":"Martelli","year":"2021","journal-title":"Blood"},{"key":"2024010808153718500_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"2024010808153718500_bib8","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2009-12-256149","article-title":"Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition","volume":"116","author":"Leong","year":"2010","journal-title":"Blood"},{"key":"2024010808153718500_bib9","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/2159-8290.CD-21-0177","article-title":"Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy","volume":"11","author":"Wu","year":"2021","journal-title":"Cancer Discov"},{"key":"2024010808153718500_bib10","doi-asserted-by":"crossref","first-page":"e46667","DOI":"10.7554\/eLife.46667","article-title":"Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells","volume":"8","author":"Oka","year":"2019","journal-title":"eLife"},{"key":"2024010808153718500_bib11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"key":"2024010808153718500_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"key":"2024010808153718500_bib13","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"2024010808153718500_bib14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"2024010808153718500_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.26862","article-title":"Mutant NPM1: nuclear export and the mechanism of leukemogenesis","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"key":"2024010808153718500_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.leu.2404887","article-title":"Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules","volume":"22","author":"Liso","year":"2008","journal-title":"Leukemia"},{"key":"2024010808153718500_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"2024010808153718500_bib18","doi-asserted-by":"crossref","first-page":"e0219547","DOI":"10.1371\/journal.pone.0219547","article-title":"Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin","volume":"14","author":"Narayan","year":"2019","journal-title":"PLoS One"},{"key":"2024010808153718500_bib19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest"},{"key":"2024010808153718500_bib20","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1200\/JCO.2011.41.1116","article-title":"Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation","volume":"31","author":"Hofmann","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024010808153718500_bib21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood"},{"key":"2024010808153718500_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1172\/JCI126116","article-title":"Cellular therapy against public neoantigens","volume":"129","author":"Armistead","year":"2019","journal-title":"J Clin Invest"},{"key":"2024010808153718500_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"2024010808153718500_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.2020008211","article-title":"How I diagnose and treat NPM1-mutated AML","volume":"137","author":"Falini","year":"2021","journal-title":"Blood"},{"key":"2024010808153718500_bib25","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1002\/ajh.26946","article-title":"The NPM1 mutant defines AML irrespective of blast count","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"key":"2024010808153718500_bib26","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood-2006-03-007013","article-title":"Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia","volume":"108","author":"Falini","year":"2006","journal-title":"Blood"},{"key":"2024010808153718500_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"2024010808153718500_bib28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carryng nuclephosmin 1 (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"key":"2024010808153718500_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"2024010808153718500_bib30","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2005-03-0899","article-title":"Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype","volume":"106","author":"Cazzaniga","year":"2005","journal-title":"Blood"},{"key":"2024010808153718500_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.leu.2404519","article-title":"Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12","volume":"21","author":"Thiede","year":"2007","journal-title":"Leukemia"},{"key":"2024010808153718500_bib32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2353\/jmoldx.2008.070166","article-title":"An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia","volume":"10","author":"Ottone","year":"2008","journal-title":"J Mol Diagn"},{"key":"2024010808153718500_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2353\/jmoldx.2008.070167","article-title":"A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis","volume":"10","author":"Szankasi","year":"2008","journal-title":"J Mol Diagn"},{"key":"2024010808153718500_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2353\/jmoldx.2008.080019","article-title":"Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies","volume":"10","author":"Wertheim","year":"2008","journal-title":"J Mol Diagn"},{"key":"2024010808153718500_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2008.07205.x","article-title":"A rapid, one step assay for simultaneous detection of FLT3\/ITD and NPM1 mutations in AML with normal cytogenetics","volume":"142","author":"Huang","year":"2008","journal-title":"Br J Haematol"},{"key":"2024010808153718500_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/CBM-2009-0583","article-title":"Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications","volume":"5","author":"Ma","year":"2009","journal-title":"Cancer Biomark"},{"key":"2024010808153718500_bib37","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"2024010808153718500_bib38","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1182\/bloodadvances.2022009008","article-title":"AML Samples show high concordance in detection of mutations by NGS at local institutions versus central laboratories","volume":"7","author":"Borate","year":"2023","journal-title":"Blood Adv"},{"key":"2024010808153718500_bib39","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2005-11-4745","article-title":"Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML","volume":"107","author":"Falini","year":"2006","journal-title":"Blood"},{"key":"2024010808153718500_bib40","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","article-title":"Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field","volume":"35","author":"Falini","year":"2021","journal-title":"Leukemia"},{"key":"2024010808153718500_bib41","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.leu.2404699","article-title":"Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas","volume":"21","author":"Falini","year":"2007","journal-title":"Leukemia"},{"key":"2024010808153718500_bib42","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/jha2.445","article-title":"NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring","volume":"3","author":"Wang","year":"2022","journal-title":"EJHaem"},{"key":"2024010808153718500_bib43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2009.017822","article-title":"Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help","volume":"95","author":"Falini","year":"2010","journal-title":"Haematologica"},{"key":"2024010808153718500_bib44","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41375-018-0299-2","article-title":"IDH1-R132 changes vary according to NPM1 and other mutations status in AML","volume":"33","author":"Falini","year":"2019","journal-title":"Leukemia"},{"key":"2024010808153718500_bib45","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2010-01-266908","article-title":"A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias","volume":"116","author":"Gruszka","year":"2010","journal-title":"Blood"},{"key":"2024010808153718500_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41408-023-00909-4","article-title":"Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study","volume":"13","author":"Matarraz","year":"2023","journal-title":"Blood Cancer J"},{"key":"2024010808153718500_bib47","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2015.129346","article-title":"NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features","volume":"100","author":"Luskin","year":"2015","journal-title":"Haematologica"},{"key":"2024010808153718500_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/bjh.18808","article-title":"NPM1-mutated AML with starry sky pattern","volume":"202","author":"Falini","year":"2023","journal-title":"Br J Haematol"},{"key":"2024010808153718500_bib49","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"},{"key":"2024010808153718500_bib50","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000531101","article-title":"Acute myeloid leukemia with NPM1 mutation and disseminated leukaemia cutis: achievement of molecular complete remission by venetoclax\/azacytidine combination in a very old patient","volume":"146","author":"Niscola","year":"2023","journal-title":"Acta Haematol"},{"key":"2024010808153718500_bib51","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1080\/10428194.2023.2185091","article-title":"Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group","volume":"64","author":"Ramia de Cap","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"2024010808153718500_bib52","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","article-title":"Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group trials, 1980\u20132008","volume":"34","author":"Ganzel","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024010808153718500_bib53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jmoldx.2019.11.004","article-title":"Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival","volume":"22","author":"Werstein","year":"2020","journal-title":"J Mol Diagn"},{"key":"2024010808153718500_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10428194.2012.701739","article-title":"Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia","volume":"54","author":"Konoplev","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2024010808153718500_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3343\/alm.2016.36.3.263","article-title":"Minor BCR-ABL1-positive acute myeloid leukemia associated with the NPM1 mutation and FLT3 internal tandem duplication","volume":"36","author":"Kim","year":"2016","journal-title":"Ann Lab Med"},{"key":"2024010808153718500_bib56","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2008.17","article-title":"NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features","volume":"22","author":"Andersen","year":"2008","journal-title":"Leukemia"},{"key":"2024010808153718500_bib57","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"2024010808153718500_bib58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.leu.2405078","article-title":"Genetics of therapy-related myelodysplasia and acute myeloid leukemia","volume":"22","author":"Pedersen-Bjergaard","year":"2008","journal-title":"Leukemia"},{"key":"2024010808153718500_bib59","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"2024010808153718500_bib60","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood.2022018108","article-title":"Overlapping features of therapy-related and de novo NPM1-mutated AML","volume":"141","author":"Othman","year":"2023","journal-title":"Blood"},{"key":"2024010808153718500_bib61","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"2024010808153718500_bib62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"key":"2024010808153718500_bib63","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2024010808153718500_bib64","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"key":"2024010808153718500_bib65","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"key":"2024010808153718500_bib66","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv"},{"key":"2024010808153718500_bib67","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1002\/ajh.24861","article-title":"Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"92","author":"Vallapureddy","year":"2017","journal-title":"Am J Hematol"},{"key":"2024010808153718500_bib68","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.189886","article-title":"NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents","volume":"103","author":"Prata","year":"2018","journal-title":"Haematologica"},{"key":"2024010808153718500_bib69","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMc1608739","article-title":"Genomic classification in acute myeloid leukemia","volume":"375","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2024010808153718500_bib70","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.2022018582","article-title":"Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification","volume":"141","author":"Angenendt","year":"2023","journal-title":"Blood"},{"key":"2024010808153718500_bib71","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41375-020-0872-3","article-title":"Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged &lt;60 years","volume":"34","author":"Eisfeld","year":"2020","journal-title":"Leukemia"},{"key":"2024010808153718500_bib72","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2022-167138","article-title":"Machine learning allows the identification of new co-mutational pattern with prognostic implication in NPM1 mutated AML- Results of the European Harmony Alliance","volume":"140","author":"S\u00e1nchez","year":"2022","journal-title":"Blood"},{"key":"2024010808153718500_bib73","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1002\/ajh.26730","article-title":"Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1","volume":"97","author":"Wright","year":"2022","journal-title":"Am J Hematol"},{"key":"2024010808153718500_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/ejh.13979","article-title":"Impact of secondary-type mutations in NPM1 mutated AML","volume":"111","author":"Zhou","year":"2023","journal-title":"Eur J Haematol"},{"key":"2024010808153718500_bib75","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification","author":"Eckardt","year":"2023.","journal-title":"Leukemia"},{"key":"2024010808153718500_bib76","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood"},{"key":"2024010808153718500_bib77","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2022-162377","article-title":"FLAG-Ida combined with gemtuzumab ozogamicin (GO) improves event-free survival in younger patients with newly diagnosed acute myeloid leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 Trial","volume":"140","author":"Russell","year":"2022","journal-title":"Blood"},{"key":"2024010808153718500_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024010808153718500_bib79","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3324\/haematol.2022.282639","article-title":"Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival","volume":"108","author":"Tettero","year":"2023","journal-title":"Haematologica"},{"key":"2024010808153718500_bib80","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"2024010808153718500_bib81","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"2024010808153718500_bib82","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","article-title":"Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study","volume":"7","author":"Scott","year":"2023","journal-title":"Blood Adv"},{"key":"2024010808153718500_bib83","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13038","article-title":"Quantification of rare NPM1 mutation subtypes by digital PCR","volume":"167","author":"Bacher","year":"2014","journal-title":"Br J Haematol"},{"key":"2024010808153718500_bib84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","article-title":"Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations","volume":"19","author":"Mencia-Trinchant","year":"2017","journal-title":"J Mol Diagn"},{"key":"2024010808153718500_bib85","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jmoldx.2017.04.008","article-title":"NPM1 for MRD? Droplet like it's hot!","volume":"19","author":"Wertheim","year":"2017","journal-title":"J Mol Diagn"},{"key":"2024010808153718500_bib86","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"2024010808153718500_bib87","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40291-019-00436-8","article-title":"Clinical validation and implementation of a measurable residual disease assay for NPM1 in acute myeloid leukemia by error-corrected next-generation sequencing","volume":"23","author":"Ritterhouse","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"2024010808153718500_bib88","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2020.260133","article-title":"Minimal residual disease monitoring in acute myeloid leukemia with non-A\/B\/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use","volume":"106","author":"Lesieur","year":"2021","journal-title":"Haematologica"},{"key":"2024010808153718500_bib89","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024010808153718500_bib90","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kronke","year":"2011","journal-title":"J Clin Oncol"},{"key":"2024010808153718500_bib91","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"2024010808153718500_bib92","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"2024010808153718500_bib93","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"key":"2024010808153718500_bib94","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18887","article-title":"A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure","volume":"202","author":"Sartor","year":"2023","journal-title":"Br J Haematol"},{"key":"2024010808153718500_bib95","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"key":"2024010808153718500_bib96","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy","author":"Othman","year":"2023","journal-title":"Blood"},{"key":"2024010808153718500_bib97","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.18632\/oncotarget.2196","article-title":"MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin","volume":"5","author":"Lambert","year":"2014","journal-title":"Oncotarget"},{"key":"2024010808153718500_bib98","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"key":"2024010808153718500_bib99","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024010808153718500_bib100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"key":"2024010808153718500_bib101","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"key":"2024010808153718500_bib102","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"key":"2024010808153718500_bib103","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"2024010808153718500_bib104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"2024010808153718500_bib105","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1038\/s41598-023-38037-5","article-title":"Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience","volume":"13","author":"Jager","year":"2023","journal-title":"Sci Rep"},{"key":"2024010808153718500_bib106","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"key":"2024010808153718500_bib107","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv"},{"key":"2024010808153718500_bib108","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2011.044388","article-title":"Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse","volume":"96","author":"Sockel","year":"2011","journal-title":"Haematologica"},{"key":"2024010808153718500_bib109","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"2024010808153718500_bib110","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","article-title":"FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML","volume":"37","author":"Othman","year":"2023","journal-title":"Leukemia"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0144\/3379918\/bcd-23-0144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0144\/3389094\/bcd-23-0144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/8\/3400221\/8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/8\/3400221\/8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:16:42Z","timestamp":1704701802000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/1\/8\/732331\/Criteria-for-Diagnosis-and-Molecular-Monitoring-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,7]]},"published-print":{"date-parts":[[2024,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0144","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}